HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.

Jo Sasame Naoki Ikegaya Masahito Kawazu Manabu NatsumedaTakahiro HayashiMasataka IsodaKaishi SatomiArata Tomiyama Akito OshimaHirokuni HonmaYohei MiyakeKatsuhiro TakabayashiTaishi NakamuraToshihide UenoYuko MatsushitaHiromichi IwashitaYu KanemaruHidetoshi MurataAkihide RyoKeita TerashimaShoji YamanakaYukihiko FujiiHiroyuki Mano Takashi KomoriKoichi IchimuraDaniel P Cahill Hiroaki WakimotoTetsuya YamamotoKensuke Tateishi

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

The combination of an HSP90 inhibitor with BRAF or MEK inhibitors can overcome the limitations of the current therapeutic strategies for BRAFV600E-mutant HGG.

Keyphrases

high grade
wild type
heat shock protein
heat shock
heat stress
low grade
pi k akt
single molecule
metastatic colorectal cancer
signaling pathway
oxidative stress
cell proliferation